MaxCyte Inc. | Cash Flow

Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
613.00
1,115.70
946.10
2,479.40
7,700.60
6,651.50
Depreciation, Depletion & Amortization
74.50
55.90
61.10
78.30
111.00
258
Other Funds
-
-
442.90
-
-
1,121.40
Funds from Operations
496.30
954.40
826.00
2,226.50
7,111.50
5,272.10
Changes in Working Capital
139.40
215.10
707.80
496.00
402.90
2,593
Net Operating Cash Flow
356.90
1,169.50
118.10
1,730.50
7,514.30
7,865.10
Capital Expenditures
31.70
89.30
61.90
162.20
473.40
Net Investing Cash Flow
31.70
89.30
61.90
162.20
473.40
Issuance/Reduction of Debt, Net
29.60
1,828.70
35.60
59.10
11.10
Net Financing Cash Flow
29.60
2,864.60
472.60
8,796.30
18,559.60
Net Change in Cash
418.10
1,605.80
652.60
6,903.70
10,571.90
Free Cash Flow
388.50
1,258.80
180.00
1,892.70
7,987.80
Change in Capital Stock
-
1,035.90
5.90
8,855.40
18,570.70

About MaxCyte

View Profile
Address
22 Firstfield Road
Gaithersburg Maryland 20878
United States
Employees -
Website http://www.maxcyte.com
Updated 07/08/2019
MaxCyte, Inc. enages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include MaxCyte STX, MaxCyte VLX, and MaxCyte GT.